Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Mercedes Rincon
University of Vermont & St Agric College, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Mitotherapeutix
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Mitotherapeutix is a company with no profit, set up in 2014 for commercializing a liver and cancer treatment which Professor Rincon discovered in relation to the MCJ protein and siRNA. The initial focus of the company is the potential use of the protein MCJ as a regulator of cellular metabolism and through its regulation controlling liver disease and cancer.
Professor Rincon has disclosed an SFI in Mitotherapeutix which includes ownership of shares, a management role, and the ownership of some Intellectual Property rights.
The commercial focus of Mitotherapeutix and the scope of this research project are related, and the outcome of the research project is related to the value of Mitotherapeutix and its Intellectual Property rights.
Metabolic Regulation of Caspases and Survival in T Cells
The survival of effector T cells to the memory state is of fundamental importance to protection from infection as well as in autoimmune disorders. IL-15 has been implicated in the pathogenesis of various autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, ulcerative colitis, celiac syndrome, and psoriasis. IL- 15 also indues the inflammatory cytokines TNF-? and IL-1? and is important in homeostatic proliferation of T cells. It is now appreciated that augmented homeostatic proliferation may be a driving force in several autoimmune disorders. IL-15 also drives a metabolic state characterized by high oxidative phosphorylation and low glycolysis, and we observe that this is associated with low levels of caspase-3 activity due to its inactivation by S-nitrosylation. Regulation of active caspases in cycling T cells is paramount to understanding T cell survival during both homeostatic proliferation as well as during the generation of memory T cells. We have also identified a novel protein, MCJ as a regulator of Complex I activity in the electron transport chain, and hence of mitochondrial respiration. IL-15 silences MCJ expression. The significance of the proposed studies is that it links for the first time the cytokine environment to metabolism via MCJ, and regulation of effector caspase-3 as a major determinant of cell survival. It then applies this to human rheumatoid arthritis synovium. The study presents a focused series of experiments on the metabolic regulation of caspase-3 activity by IL-15 and applies this to a real human autoimmune disease. It also suggests potential therapeutic options in autoimmune disorders by regulating IL-15, MCJ, or metabolism.
Filed on May 17, 2017.
Tell us what you know about Mercedes Rincon's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Mercedes Rincon”
Name | Institution | Type | Company | Disclosed Value |
---|---|---|---|---|
Mercedes Rincon | University of Vermont & St Agric College | Conflict of Interest | Mitotherapeutix | Value cannot be readily determined |
Mercedes Rincon | University of Vermont & St Agric College | Conflict of Interest | Mitotherapeutix | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.